Clinuvel Pharmaceuticals Limited (CUV.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Philippe Jacques Wolgen M.B.A., M.D.
|
CEO, MD & Director | 4.31M | -- | 1963 |
|
Mr. Peter Vaughan
|
Chief Financial Officer | 349.68k | -- | -- |
|
Mr. Lachlan Hay
|
Chief Operations Officer | 634.98k | -- | -- |
|
Dr. Dennis J. Wright BPharm, M.Sc., Ph.D.
|
Chief Scientific Officer | 377.81k | -- | -- |
|
Mr. Malcolm Bull
|
Head of Australian Operations & Investor Relations | -- | -- | -- |
|
Dr. Azza Hamila
|
Head of Quality Assurance & Drug Safety | -- | -- | -- |
|
Ms. Claire Newstead-Sinclair C.A.
|
Company Secretary | -- | -- | -- |
|
Dr. Linda Teng
|
Director of North American Operations | -- | -- | -- |
|
Dr. Emilie Rodenburger
|
Director of Global Clinical Affairs | -- | -- | -- |
Clinuvel Pharmaceuticals Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Corporate Governance
Upcoming Events
August 27, 2026 at 6:12 AM UTC
Clinuvel Pharmaceuticals Limited Earnings Date
Recent Events
September 3, 2026 at 12:00 AM UTC
Ex-Dividend Date
